The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma
Open accessAbstract
Purpose: The CpG island methylator phenotype (CIMP) may be associated with development of malignancy through coordinated inactivation of tumor suppressor and tumor-related genes (TRG) and methylation of multiple noncoding, methylated-in-tumor (MINT) loci. These epigenetic changes create a distinct CIMP pattern that has been linked to recurrence and survival in gastrointestinal cancers. Because epigenetic inactivation of TRGs also has been shown in malignant melanoma, we hypothesized the existence of a clinically significant CIMP in cutaneous melanoma progression. Experimental Design: The methylation status of the CpG island promoter region of TRGs related to melanoma pathophysiology (WIF1, TFPI2, RASSF1A, RARβ2, SOCS1, and GATA4) and a panel of MINT loci (MINT1, MINT2, MINT3, MINT12, MINT17, MINT25, and MINT31) in primary and metastatic tumors of different clinical stages (n = 122) was assessed. Results: Here, we show an increase in hypermethylation of the TRGs WIF1, TFPI2, RASSF1A, and SOCS1 with advancing clinical tumor stage. Furthermore, we find a significant positive association between the methylation status of MINT17, MINT31, and TRGs. The methylation status of MINT31 is associated with disease outcome in stage III melanoma. Conclusions: These findings show the significance of a CIMP pattern that is associated with advancing clinical stage of malignant melanoma. Future prospective large-scale studies may determine if CIMP-positive primary melanomas are at high risk of metastasis or recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Cited by
Sidhu, P., Cantisani, V., Dietrich, C., Gilja, O., Saftoiu, A., Bartels, E., Bertolotto, M., Calliada, F., Clevert, D.-A., Cosgrove, D., et al. (2018) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-0586-1107 · Cited by 1,086
Epigenetic modifications as therapeutic targets
Kelly, T. K., De Carvalho, D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 793
Epigenetics in health and disease
Zhang, L., Lu, Q., & Chang, C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3449-2_1 · Cited by 689
Epigenetic regulation in human melanoma: past and future
Sarkar, D., Leung, E. Y., Baguley, B. C., Finlay, G. J., & Askarian-Amiri, M. E. (2015) · Epigenetics · doi:10.1080/15592294.2014.1003746 · Cited by 289
Identification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas
Barreau, O., Assié, G., Wilmot-Roussel, H., Ragazzon, B., Baudry, C., Perlemoine, K., René-Corail, F., Bertagna, X., Dousset, B., Hamzaoui, N., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2993 · Cited by 132
Metadata
- Authors
- Tanemura, A., Terando, A. M., Sim, M.-S., van Hoesel, A. Q., de Maat, M. F. G., Morton, D. L., & Hoon, D. S. B.
- Venue
- Clinical Cancer Research
- Published
- 2009-02-27
- Volume
- 15
- Issue
- 5
- Pages
- 1801-1807
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2149071620
- Cited by
- 206
- References
- 1
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-1361
- The paper
- Tanemura, A., Terando, A. M., Sim, M.-S., van Hoesel, A. Q., de Maat, M. F. G., Morton, D. L., & Hoon, D. S. B. (2009). CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-1361
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.